PROLEASE HGH IN CHILDREN WITH GROWTH FAILURE DUE TO GROWTH HORMONE DEFICIENCY

因生长激素缺乏而导致生长迟缓的儿童中的 HGH 表达

• 批准号: 6278086
• 负责人: THOMAS MOSHANG
• 金额: $ 2.4万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278086
• 关键词: child (0-11); clinical research; drug screening /evaluation; hormone therapy; human subject; human therapy evaluation; hypoglycemia; pharmacokinetics; postnatal growth disorder; slow release drug; somatotropin

This study is a short-term trial of a new formulation of a long acting growth hormone (hGH) to evaluate its safety and efficacy. The treatment of growth hormone deficiency (GHD) since the late 1960's initially with cadaveric hGH and then, subsequently, with recombinant hGH, has not changed in terms of method of administration of the hormone. The children were treated with frequent injections of hGH. Initially, this was three times per week intramuscularly and present standard treatment is daily subcutaeous injections of hGH. The present drug to be tested is a commercial growth hormone combined into a polyacrimide substance presently used as a dissolvable suture material to provide, theoretically, a slow release long acting hGH. This study is intended to evaluate possible side effects and short term efficacy. Future plans include a long term study of this drug to evaluate efficacy.

这项研究是对长期表演的新表述的短期试验 生长激素（HGH）评估其安全性和功效。处理 自1960年代后期以来，生长激素缺乏症（GHD）最初 尸体HGH，然后随后使用重组HGH，没有 在激素的给药方法方面发生了变化。孩子们 经常注射HGH。最初，这是三个 每周肌肉内和目前的标准处理是每天的 HGH的亚曲霉注射。目前要测试的药物是 目前，商业生长激素合并成聚ac酰亚胺物质 从理论上讲，用作可溶解的缝合材料可提供的 释放长期表演HGH。这项研究旨在评估可能的一面 效果和短期功效。 未来计划包括一项长期研究 该药物评估功效。